Hims to acquire UK-based startup Zava as it expands international presence
New York:
Telehealth platform
Hims & Hers said on Tuesday it will acquire London-based startup
Zava
for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.
The move comes as Hims is adjusting to a regulatory ban in the United States on manufacturing mass copies of Novo Nordisk's popular
weight-loss drug
Wegovy, that took effect on May 22. Hims began offering copies of Wegovy in 2024, and saw a boost in its revenues, when the branded version of the highly in-demand drug was in shortage.
Shares of the telehealth firm have dropped nearly 9% in the last two weeks. It recently entered into an agreement with Novo to help patients access brand-name Wegovy, and plans to enter the market for low testosterone and menopause treatments in pursuit of new growth opportunities.
Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its second-quarter results expected in August.
It plans to fund the acquisition through cash on its balance sheet at closing. The deal is expected to close in the second half of this year. Backed by equity firm HPE Growth, Zava provides medical consultations and delivery of prescription medicines - including weight loss drugs Mounjaro and Wegovy - to its more than 1 million customers across United Kingdom, Germany, France and Ireland.
Hims said it plans to introduce personalized skin care, weight loss and other offerings for patients in these markets and will introduce an option for patients to interact with their healthcare providers in local languages.
Last week, Hims also said it will cut about 4% of its workforce but still plans to hire for roles related to its long-term growth strategy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
US weekly jobless claims rise for second straight week
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The number of Americans filing new applications for unemployment benefits last week increased for a second straight week, pointing to softening labor market conditions amid mounting economic headwinds from claims for state unemployment benefits rose 8,000 to a seasonally adjusted 247,000 for the week ended May 31, the Labor Department said on Thursday. Economists polled by Reuters had forecast 235,000 claims for the latest are generally hoarding workers after struggling to find labor during and after the COVID-19 pandemic, but mounting uncertainty because of President Donald Trump's tariffs is forcing some to layoff Federal Reserve's Beige Book report on Wednesday showed "comments about uncertainty delaying hiring were widespread," noting that "all districts described lower labor demand, citing declining hours worked and overtime, hiring pauses and staff reduction plans. It said while some districts reported layoffs in certain sectors, "these layoffs were not pervasive."An Institute for Supply Management survey also made similar observations, reporting steady employment in the services sector in May, but also pointing out that "higher scrutiny is being placed on all jobs that need to be filled."Economists expect claims this month will break above their 205,000-243,000 range for 2025, mostly driven by difficulties adjusting the data for seasonal fluctuations and following a similar pattern in recent number of people receiving benefits after an initial week of aid, a proxy for hiring, slipped 3,000 to a seasonally adjusted 1.904 million during the week ending May 24, the claims report showed. The elevation in the so-called continuing claims aligns with consumers' ebbing confidence in the labor market.A separate report from global outplacement firm Challenger, Gray and Christmas showed U.S-based employers announced 93,816 job cuts in May, down 12% from April. Layoffs were, however, 47% higher from a year claims data have no bearing on the Labor Department's closely watched employment report for May, scheduled to be released on Friday, as it falls outside the survey period. Nonfarm payrolls likely increased by 130,000 jobs last month after advancing by 177,000 in April, a Reuters survey of economists showed. The unemployment rate is forecast being unchanged at 4.2%.
Time of India
25 minutes ago
- Time of India
Stablecoin bigwig Circle set to make its debut on the New York Stock Exchange
Crypto enthusiasts will be watching the stock market Thursday as the U.S.-based issuer of one of most popular cryptocurrencies makes its debut on the New York Stock Exchange. Circle Internet Group issues USDC, a stablecoin that can be traded at a one-to-one ratio for U.S. dollars, and EURC, which can similarly be traded for euros. Stablecoins are a fast-growing corner of the cryptocurrency industry that offer a buffer against volatility because they are pegged to real-world assets, like U.S. dollars or gold. That makes them a much more reliable means of conducting commercial transactions than other forms of crypto. Interest in Circle's initial public offering is high. The company's underwriters priced the offering at $31 per share Wednesday, up from an expected price of $27 to $28. The number of shares being sold was raised to 34 million from 32 million. Circle will trade on the NYSE under the symbol "CRCL." The dominant player in the stablecoin field is El Salvador-based Tether, which has the stablecoin known as USDT that currently has about $150 billion in circulation. USDC is the second most popular stablecoin market cap, with about $60 billion in circulation. Live Events Circle said in a regulatory filing that USDC has been used for more than "$25 trillion in onchain transactions" since its launch in 2018. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories Revenue-wise the company has seen tremendous growth, going from just $15 million in 2020 to $1.7 billion in 2024. Stablecoin issuers make profits by collecting the interest on the assets they hold in reserve to back their stablecoins. Circle said USDC is backed by "cash, short-dated US Treasuries and overnight US Treasury repurchase agreements with leading global banks." Circle's IPO comes amid a push by the Trump administration and the crypto industry to pass legislation that would regulate how stablecoin issuers operate in the U.S. A Senate bill advanced last month with bipartisan support. There is also growing competition in the stablecoin field. A crypto enterprise partly owned by the Trump family just launched its own stablecoin, USD1. Circle said its long track record and values - the company says its mission statement is "to raise global economic prosperity through the frictionless exchange of value" - will help it stand apart in the field.
Time of India
35 minutes ago
- Time of India
UK warns about 'skinny jabs' if trying to get pregnant
London:The UK's medicine regulator warned Thursday against taking " skinny jabs " to fight weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies. The Medicines and Healthcare products Regulatory Agency (MHRA) said popular jabs like Ozempic and Wegovy "must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding". It urged women to use "effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant". "Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible... because there is not enough safety data to know whether taking the medicine could cause harm to the baby," it added. Rebecca Reynolds, a professor of metabolic medicine at the University of Edinburgh, said there was "hardly any available data from human studies" to know if the weight loss drugs were safe in pregnancy. "The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans," she added. The MHRA also warned about the impact of another weight-loss and diabetes injection, Mounjaro, on the effectiveness of oral contraception for people who are overweight. "Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," it said. Ying Cheong, a consultant in reproductive medicine at the University of Southampton, called the MHRA's advice "both timely and necessary". "Gastrointestinal side-effects such as vomiting and diarrhoea can impair oral contraceptive absorption, increasing the risk of unintended pregnancy," he said.
